DAW 24th January 2026, Mains Answer Writting 2027

DAW 24th January 2026, Mains Answer Writting 2027

Question

Why is AMR described as a “silent pandemic”? Discuss how non-therapeutic antibiotic use in livestock and unregulated OTC antibiotic sales contribute to the growing AMR burden in India. (250 Words, 15 Marks).

Model Answer

Approach: Introduction:

  • Briefly define Antimicrobial Resistance (AMR) and explain why it is termed a “silent pandemic”.

  • Link the concept directly to the Indian context, highlighting non-therapeutic antibiotic use in livestock and unregulated OTC sales as key drivers.

Body:

  • Explain why AMR is “silent”: gradual spread, dispersed mortality, invisible ecological transmission, and weak surveillance.

  • Substantiate with data/examples: AMR-attributable deaths, neonatal sepsis, resistance carriage, hospital resistance levels.

  • Discuss livestock dimension: growth-promoter use, food-chain transmission, export rejections.

  • Discuss human health dimension: pill-popping culture, misuse of Watch antibiotics, Schedule H1 enforcement gaps.

Conclusion:

  • Reiterate AMR as a systemic One Health crisis threatening modern medicine.

  • End with forward-looking solutions- regulation, stewardship, surveillance and behavioural change- to preserve antibiotic efficacy.

Introduction:

  • Antimicrobial Resistance (AMR) is the ability of microorganisms- bacteria, viruses, fungi and parasites- to withstand medicines that once treated them effectively. It is termed a “silent pandemic” because it spreads gradually and invisibly across human, animal and environmental systems, steadily eroding routine medical care without dramatic outbreaks. In India, this crisis is being driven by non-therapeutic antibiotic use in livestock and unregulated over-the-counter (OTC) antibiotic sales, raising the risk of a return to a pre-antibiotic era where common infections may again become fatal.

Body: Why AMR is termed a “Silent Pandemic”? AMR is described as a silent pandemic because its spread and impact are gradual, diffuse and largely invisible, unlike sudden outbreaks such as COVID-19.

  • High but dispersed mortality burden: The Institute of Health Metrics and Evaluation estimates that 2.67 lakh deaths in India in 2021 were attributable to AMR, while 1.27 million global deaths occurred in 2019.

  • Disproportionate impact on vulnerable groups: In India, over 50,000 newborns die annually from drug-resistant sepsis, directly undermining Infant Mortality Rate (IMR) reduction efforts.

  • Erosion of routine medical care: Antibiotics are central to infection control in surgeries, chemotherapy and childbirth. Rising resistance makes procedures such as C-sections, joint replacements and cancer therapy increasingly risky.

  • Invisible ecological spread: Resistant organisms circulate silently through gut micro-biomes, water, soil and food chains. One study found 83% of Indians carrying resistant bacteria, indicating widespread but unnoticed transmission.

  • Surveillance blind spots: AMR data in India is largely drawn from tertiary hospitals, masking resistance patterns in rural and primary healthcare settings.

Role of Non-Therapeutic Antibiotic Use in Livestock: The livestock and aquaculture sectors significantly accelerate AMR through non-therapeutic antibiotic use, often termed the “growth promoter epidemic.”

  • Growth promotion over treatment: Antibiotics, including last-resort human drugs like colistin, have been routinely used to promote faster animal growth. India is the 4th largest consumer of animal antibiotics globally.

  • Scale of misuse: Antibiotic use in animals is projected to increase by 82% by 2030, intensifying resistance selection pressure.

  • Food-chain transmission: Resistant bacteria pass from meat and fish to humans. Studies report 100% resistance to ampicillin in shrimp samples from Kerala retail markets.

  • Economic consequences: Indian seafood exports have faced repeated rejections by the US FDA and EU due to antibiotic residues, harming trade and livelihoods.

Impact of Unregulated OTC Antibiotic Sales: Unregulated over-the-counter (OTC) antibiotic sales have created a pill-popping culture in India.

  • Misuse for viral infections: Antibiotics are widely used for colds, coughs and flu, against which they are ineffective.

  • Overuse of high-risk antibiotics: In 2022, about 59% of antibiotic consumption in India came from the WHO “Watch” category, reflecting weak stewardship.

  • Regulatory enforcement gaps: Despite Schedule H1 restrictions and the Red Line Campaign, lax enforcement allows pharmacies to dispense loose pills, encouraging incomplete courses.

  • Clinical outcomes: Consequently, 1 in 10 patients admitted to Indian hospitals is resistant to last-resort antibiotics, increasing treatment failure and healthcare costs.

Way Forward / Suggestions:

  • Strictly enforce Schedule H1 and ban OTC antibiotic sales nationwide, using digital prescription audits and penalties.

  • Fully operationalise NAP-AMR 2.0 (2025–29) through mandatory State AMR Action Plans and One Health coordination.

  • Eliminate non-therapeutic antibiotic use in livestock, while incentivising animal vaccination and biosecurity measures.

  • Expand AMR surveillance and diagnostics beyond tertiary hospitals using a hub-and-spoke laboratory model.

  • Strengthen Behaviour Change Communication (BCC) to break the pill-popping culture and promote rational antibiotic use.

Conclusion:

  • AMR is a “silent pandemic” because it kills not through sudden outbreaks but by steadily eliminating treatment options, undermining modern medicine from within. In India, non-therapeutic antibiotic use in livestock and unregulated OTC sales together create powerful reservoirs of resistance across humans, animals and the environment. Addressing this challenge requires sustained political will, strict regulation, and a robust One Health approach to safeguard the future of effective antimicrobial therapy.